Lyudmila V. Korshunova
Lyudmila V. Korshunova has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Oleg Mikhaylovich Uryas'Ev
Ryazan State Medical University named after academician I.P. Pavlov
5 shared publications - Anton V. Shakhanov
Ryazan State Medical University named after academician I.P. Pavlov
3 shared publications - A. E. Chervyakov
Federal State Budgetary Educational Institution of Higher Professional “Ryazan State Medical University”, Ministry of Healthcare of the Russian Federation
2 shared publications - Aleksandra V. Solov'YEva
Ryazan State Medical University named after academician I.P. Pavlov
2 shared publications - Elena V. Stezhkina
Federal State Budgetary Educational Institution of Higher Education “Ryazan State Medical University named after Academician I. P. Pavlov” of the Ministry of Health of the Russian Federation
2 shared publications A. B. Шаханов
Федеральное государственное бюджетное образовательное учреждение высшего образования «Рязанский государственный медицинский университет имени академика И.П.Павлова» Министерства здравоохранения Российской Федерации
1 shared publication
Latest Publications
- 17 April 2026
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 36 (2)
The experience of using triple targeted therapy (elexacaftor/ tezacaftor/ivacaftor) in a patient with cystic fibrosis complicated by cystic fibrosis-related diabetes
This article discusses the clinical experience of using triple targeted therapy (elexacaftor/tezacaftor/ivacaftor) in a patient with cystic fibrosis complicated by cystic fibrosis-related diabetes. The description includes details on the diagnostic process, the features of the disease course, and treatment approaches. In addition, the work pays special attention to the use of targeted drugs, as well as the need for an integrated approach to managing the condition of patients with combined disorders. To date, there has been insufficient research on the efficacy of the drug elexacaftor/ tezacaftor/ivacaftor and its effects on patients with comorbid conditions, particularly those suffering from cystic fibrosis-related diabetes. The aim was to highlight modern research on this topic and to assess the effect of triple targeted therapy on the clinical manifestations of the disease. Results. The patient showed significant improvement in the functional state of the lungs, control of blood glucose levels, and overall quality of life. Conclusion. The article summarizes the importance of an individualized approach to therapy that considers both genetic and metabolic aspects of the disease. The conclusion emphasizes the importance of early, timely initiation of treatment to achieve optimal results and improve the prognosis of long-term life in patients with cystic fibrosis and related complications.
- 17 April 2026
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 36 (2)
The experience of using triple targeted therapy (elexacaftor/ tezacaftor/ivacaftor) in a patient with cystic fibrosis complicated by cystic fibrosis-related diabetes
This article discusses the clinical experience of using triple targeted therapy (elexacaftor/tezacaftor/ivacaftor) in a patient with cystic fibrosis complicated by cystic fibrosis-related diabetes. The description includes details on the diagnostic process, the features of the disease course, and treatment approaches. In addition, the work pays special attention to the use of targeted drugs, as well as the need for an integrated approach to managing the condition of patients with combined disorders. To date, there has been insufficient research on the efficacy of the drug elexacaftor/ tezacaftor/ivacaftor and its effects on patients with comorbid conditions, particularly those suffering from cystic fibrosis-related diabetes. The aim was to highlight modern research on this topic and to assess the effect of triple targeted therapy on the clinical manifestations of the disease. Results. The patient showed significant improvement in the functional state of the lungs, control of blood glucose levels, and overall quality of life. Conclusion. The article summarizes the importance of an individualized approach to therapy that considers both genetic and metabolic aspects of the disease. The conclusion emphasizes the importance of early, timely initiation of treatment to achieve optimal results and improve the prognosis of long-term life in patients with cystic fibrosis and related complications.
- 22 October 2025
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 1 (3) , 19-26
Clinical and patient-reported outcomes of triple therapy (budesonide/glycopyrronium bromide/formoterol) in chronic obstructive pulmonary disease: results of the observational MINERVA study
Objective. The evaluation of clinical and patient-reported outcomes in patients with chronic obstructive pulmonary disease (COPD) treated with the triple combination of budesonide/glycopyrronium bromide/formoterol (BUD/GLY/FORM) in real-life clinical practice. Material and methods. The non-interventional MINERVA study (NCT06422676) was conducted in Russia in 2023—2024. Retrospective data were collected for a period of 12 months before the start of therapy. The prospective observation period was 24 weeks from the start of therapy. Results. The study included 200 patients, average age 64.97 years, 58.5% of patients ≥65 years and older, 87.5% of patients were male, 59% were active smokers. The average baseline CAT (COPD Assessment Test) score was 23.80. A total of 137 (68.5%) patients had moderate or severe COPD exacerbations in the previous 12 months. A total of 196 patients completed 24 weeks of treatment. The mean (95% confidence interval (CI)) change in CAR score from baseline was –8.81 (–9.85; –7.76) at week 24 and –5.63 (–6.29; –4.98) at week 12. In patients with severe exacerbations in the past year, it was –11.57 (–14.08; –9.07) and –6.22 (–7.69; –4.76), respectively; in patients with elevated baseline blood eosinophil levels, the change was –9.21 (–12.25; –6.17) and –6.21 (–8.41; –4.01), respectively. A reduction in CAT by ≥2 points by week 24 was achieved in 87% of patients (95% CI 81.53%; 91.33%). The average number of moderate exacerbations per patient decreased from 0.83 to 0.03, severe exacerbations — from 0.44 to 0.02. The therapy was characterized by high compliance, was safe and well tolerated. Conclusion. The use of BUD/GLI/FORM leads to an improvement in the condition of patients with COPD and can significantly reduce the frequency of exacerbations.
- 22 October 2025
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 1 (3) , 19-26
Clinical and patient-reported outcomes of triple therapy (budesonide/glycopyrronium bromide/formoterol) in chronic obstructive pulmonary disease: results of the observational MINERVA study
Objective. The evaluation of clinical and patient-reported outcomes in patients with chronic obstructive pulmonary disease (COPD) treated with the triple combination of budesonide/glycopyrronium bromide/formoterol (BUD/GLY/FORM) in real-life clinical practice. Material and methods. The non-interventional MINERVA study (NCT06422676) was conducted in Russia in 2023—2024. Retrospective data were collected for a period of 12 months before the start of therapy. The prospective observation period was 24 weeks from the start of therapy. Results. The study included 200 patients, average age 64.97 years, 58.5% of patients ≥65 years and older, 87.5% of patients were male, 59% were active smokers. The average baseline CAT (COPD Assessment Test) score was 23.80. A total of 137 (68.5%) patients had moderate or severe COPD exacerbations in the previous 12 months. A total of 196 patients completed 24 weeks of treatment. The mean (95% confidence interval (CI)) change in CAR score from baseline was –8.81 (–9.85; –7.76) at week 24 and –5.63 (–6.29; –4.98) at week 12. In patients with severe exacerbations in the past year, it was –11.57 (–14.08; –9.07) and –6.22 (–7.69; –4.76), respectively; in patients with elevated baseline blood eosinophil levels, the change was –9.21 (–12.25; –6.17) and –6.21 (–8.41; –4.01), respectively. A reduction in CAT by ≥2 points by week 24 was achieved in 87% of patients (95% CI 81.53%; 91.33%). The average number of moderate exacerbations per patient decreased from 0.83 to 0.03, severe exacerbations — from 0.44 to 0.02. The therapy was characterized by high compliance, was safe and well tolerated. Conclusion. The use of BUD/GLI/FORM leads to an improvement in the condition of patients with COPD and can significantly reduce the frequency of exacerbations.
- Open Access
- 8 August 2025
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 35 (4) , 608-612
Rare lung diseases: Williams – Campbell syndrome
Williams – Campbell syndrome (WCS) is a rare developmental defect characterized by deficiency or complete absence of cartilage mainly in the subsegmental bronchi. Inferiority of the cartilaginous apparatus creates favorable conditions for the development of recurrent lower respiratory tract infection and, as a consequence, the formation of bronchiectasis, which ultimately leads to the appearance and progression of respiratory failure, as well as to a decrease in the quality of life of patients. Insufficient awareness of this disease among doctors leads to later diagnosis, and complex conservative therapy in the absence of specific treatment for WCS entails a positive effect only in the short term.The aim. Demonstration of a clinical case of a rare respiratory disease – WCS in a 35-year-old man.Conclusion. This case illustrates the complexities of diagnosing and treating WCS and highlights the importance of raising awareness among healthcare workers regarding this disease.
- 8 August 2025
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 35 (4) , 608-612
Open AccessRare lung diseases: Williams – Campbell syndrome
Williams – Campbell syndrome (WCS) is a rare developmental defect characterized by deficiency or complete absence of cartilage mainly in the subsegmental bronchi. Inferiority of the cartilaginous apparatus creates favorable conditions for the development of recurrent lower respiratory tract infection and, as a consequence, the formation of bronchiectasis, which ultimately leads to the appearance and progression of respiratory failure, as well as to a decrease in the quality of life of patients. Insufficient awareness of this disease among doctors leads to later diagnosis, and complex conservative therapy in the absence of specific treatment for WCS entails a positive effect only in the short term.The aim. Demonstration of a clinical case of a rare respiratory disease – WCS in a 35-year-old man.Conclusion. This case illustrates the complexities of diagnosing and treating WCS and highlights the importance of raising awareness among healthcare workers regarding this disease.
- 21 November 2024
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 102 (7) , 510–517
Modern view on clinical phenotyping of chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a heterogeneous and multisystem disease with multiple phenotypes and a progressive increase in morbidity and mortality. This article provides a review of the current data on the identification, characterization, and features of therapy for the most common phenotypes of the disease. A literature review was conducted using medical resources such as PubMed, Google Scholar, and UpToDate, addressing issues related to phenotyping in COPD.
- 21 November 2024
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 102 (7) , 510–517
Modern view on clinical phenotyping of chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a heterogeneous and multisystem disease with multiple phenotypes and a progressive increase in morbidity and mortality. This article provides a review of the current data on the identification, characterization, and features of therapy for the most common phenotypes of the disease. A literature review was conducted using medical resources such as PubMed, Google Scholar, and UpToDate, addressing issues related to phenotyping in COPD.
- 31 December 2023
- Published by Ryazan State Medical University in Nauka Molodykh (Eruditio Juvenium)
Peculiarities of Exudative Pericarditis in Cardiac Metastasis
INTRODUCTION: Exudative pericarditis in a cancer patient is often a first manifestation of the disease and is considered a marker of a poor prognosis. According to the literature, the neoplastic etiology of a first-diagnosed exudative pericarditis is indicated by the following signs: cardiac tamponade, recurrent pericarditis, fever above 38°С, subacute course of pericarditis, absence of the effect of nonsteroidal anti-inflammatory drugs. The article presents a case report of cardiac metastasis in renal carcinoma manifested by acute exudative pericarditis in a 63-year old female patient. CONCLUSION: Diagnosis and treatment of cardiac metastasis presents difficulties in clinical practice due to the rarity of the disease, scarce symptoms, and the absence of clear recommendations for the management of such patients. Nevertheless, this rare route of metastasizing can significantly influence patient treatment and prognosis and requires cooperation between different specialists of the multidisciplinary team: oncologists, cardiologists, urologists (in case of renal cell carcinoma).
- 31 December 2023
- Published by Ryazan State Medical University in Nauka Molodykh (Eruditio Juvenium)
Peculiarities of Exudative Pericarditis in Cardiac Metastasis
INTRODUCTION: Exudative pericarditis in a cancer patient is often a first manifestation of the disease and is considered a marker of a poor prognosis. According to the literature, the neoplastic etiology of a first-diagnosed exudative pericarditis is indicated by the following signs: cardiac tamponade, recurrent pericarditis, fever above 38°С, subacute course of pericarditis, absence of the effect of nonsteroidal anti-inflammatory drugs. The article presents a case report of cardiac metastasis in renal carcinoma manifested by acute exudative pericarditis in a 63-year old female patient. CONCLUSION: Diagnosis and treatment of cardiac metastasis presents difficulties in clinical practice due to the rarity of the disease, scarce symptoms, and the absence of clear recommendations for the management of such patients. Nevertheless, this rare route of metastasizing can significantly influence patient treatment and prognosis and requires cooperation between different specialists of the multidisciplinary team: oncologists, cardiologists, urologists (in case of renal cell carcinoma).
- 26 March 2023
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 104 (2) , 165-175
The intensity of oxidative stress and systemic inflammation in patients with a combination of bronchial asthma and chronic obstructive pulmonary disease
Background. Chronic obstructive pulmonary disease and bronchial asthma, when combined in one patient, are characterized by a low level of control. Excess weight aggravates the course of obstructive diseases. The study of the features of this syntropy will improve the effectiveness of therapeutic measures. Aim. The study of the level of cytokines and carbonylated proteins in patients with a combination of bronchial asthma and chronic obstructive pulmonary disease with overweight and normal weight during an exacerbation. Material and methods. The study included 136 people: the first group a combination of bronchial asthma and chronic obstructive pulmonary disease (n=30), the second bronchial asthma (n=36), the third chronic obstructive pulmonary disease (n=29), the fourth volunteers without respiratory diseases (n=41). Each group was divided into two subgroups depending on the body mass index (less than 25 kg/m2 or 25 kg/m2 and more). The concentrations of interleukins-6 and -8, tumor necrosis factor in blood plasma were determined by enzyme immunoassay. The level of carbonylated plasma proteins was assessed spectrophotometrically. Statistical processing was performed in the Statistica 10.0 program using nonparametric criteria. The correlation of the studied parameters was assessed using the Spearman coefficient. Results. In patients with a combination of bronchial asthma and chronic obstructive pulmonary disease, statistically significant positive correlations between the levels of interleukins-6 and -8, tumor necrosis factor and carbonylated proteins were found 0.51, 0.59 and 0.55, respectively (p 0.05). Patients of the first group with overweight differed by 37.5% in higher levels of interleukin-6 compared with patients with body mass index 25 kg/m2. Conclusion. The intensity of systemic inflammation in patients with a combination of bronchial asthma and chronic obstructive pulmonary disease during exacerbation correlates with the intensity of oxidative damage.
- 26 March 2023
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 104 (2) , 165-175
The intensity of oxidative stress and systemic inflammation in patients with a combination of bronchial asthma and chronic obstructive pulmonary disease
Background. Chronic obstructive pulmonary disease and bronchial asthma, when combined in one patient, are characterized by a low level of control. Excess weight aggravates the course of obstructive diseases. The study of the features of this syntropy will improve the effectiveness of therapeutic measures. Aim. The study of the level of cytokines and carbonylated proteins in patients with a combination of bronchial asthma and chronic obstructive pulmonary disease with overweight and normal weight during an exacerbation. Material and methods. The study included 136 people: the first group a combination of bronchial asthma and chronic obstructive pulmonary disease (n=30), the second bronchial asthma (n=36), the third chronic obstructive pulmonary disease (n=29), the fourth volunteers without respiratory diseases (n=41). Each group was divided into two subgroups depending on the body mass index (less than 25 kg/m2 or 25 kg/m2 and more). The concentrations of interleukins-6 and -8, tumor necrosis factor in blood plasma were determined by enzyme immunoassay. The level of carbonylated plasma proteins was assessed spectrophotometrically. Statistical processing was performed in the Statistica 10.0 program using nonparametric criteria. The correlation of the studied parameters was assessed using the Spearman coefficient. Results. In patients with a combination of bronchial asthma and chronic obstructive pulmonary disease, statistically significant positive correlations between the levels of interleukins-6 and -8, tumor necrosis factor and carbonylated proteins were found 0.51, 0.59 and 0.55, respectively (p 0.05). Patients of the first group with overweight differed by 37.5% in higher levels of interleukin-6 compared with patients with body mass index 25 kg/m2. Conclusion. The intensity of systemic inflammation in patients with a combination of bronchial asthma and chronic obstructive pulmonary disease during exacerbation correlates with the intensity of oxidative damage.
- Open Access
- 7 October 2022
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 30 (3) , 313-322
Prospects of Hyaluronidase Therapy in Novel COVID-19 Infection with Damage to Lungs
INTRODUCTION: In recent years, the production and regulation of synthesis of hyaluronic acid in COVID-19 has been actively studied. Hyaluronan plays a significant role in development of severe lung damage in COVID-19 and is a potential therapeutic target the action on which will probably improve prognosis for patients with COVID-19. AIM: To study prospects of using bovhyaluronidaze azoximer in complex treatment of patients with COVID-19 with lung damage at the inpatient stage. MATERIALS AND METHODS: Thirty five patients (6 men and 29 women) aged 58.9 12.9 years hospitalized with COVID-19 infection, were examined. Capillary blood saturation (SpO2) was 80.1 8.6%, the volume of lung damage in X-ray computed tomography (X-ray CT) was 45.1 19.4% on the right and 40.0 19.5% on the left. All the patients received treatment according to the Temporary Guidelines: prevention, diagnosis and treatment of novel coronavirus infection. Ver. 14 (27.12.2021). Besides, as part of complex treatment for COVID-19, bovhyaluronidaze azoximer was administered intramuscularly on the 21.9 6.8th day of illness with a course of 10 injections (once in 3 days). RESULTS: In the course of comprehensive treatment including bovhyaluronidaze azoximer, increase in SpO2 was recorded: in 7 patients ― after 1 injection (4.2 1.7%), in 24 ― after 2 injections (5.4 0.6%), another 4 patients did not show any significant increase in SpO2 after the first two injections. Increase in SpO2 after the 1st injection inversely correlated with age (r = -0.34; p 0.05) and the initial saturation (r = -0.38; p 0.05). Increase in SpO2 after the second injection correlated with the day of illness on which treatment with bovhyaluronidaze azoximer began (r = -0.36; p 0.05). CONCLUSION: Use of bovhyaluronidaze azoximer in complex treatment for COVID-19 with the lung damage at the inpatient stage can be effective in younger patients with more expressed initial reduction of SpO2, and also in case of administration of the drug in the early stages of the disease. The data obtained in the pilot study, dictate the necessity of studying the level of hyaluronic acid in blood of patients with COVID-19 and lung damage and its role in risk stratification of such patients.
- 7 October 2022
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 30 (3) , 313-322
Open AccessProspects of Hyaluronidase Therapy in Novel COVID-19 Infection with Damage to Lungs
INTRODUCTION: In recent years, the production and regulation of synthesis of hyaluronic acid in COVID-19 has been actively studied. Hyaluronan plays a significant role in development of severe lung damage in COVID-19 and is a potential therapeutic target the action on which will probably improve prognosis for patients with COVID-19. AIM: To study prospects of using bovhyaluronidaze azoximer in complex treatment of patients with COVID-19 with lung damage at the inpatient stage. MATERIALS AND METHODS: Thirty five patients (6 men and 29 women) aged 58.9 12.9 years hospitalized with COVID-19 infection, were examined. Capillary blood saturation (SpO2) was 80.1 8.6%, the volume of lung damage in X-ray computed tomography (X-ray CT) was 45.1 19.4% on the right and 40.0 19.5% on the left. All the patients received treatment according to the Temporary Guidelines: prevention, diagnosis and treatment of novel coronavirus infection. Ver. 14 (27.12.2021). Besides, as part of complex treatment for COVID-19, bovhyaluronidaze azoximer was administered intramuscularly on the 21.9 6.8th day of illness with a course of 10 injections (once in 3 days). RESULTS: In the course of comprehensive treatment including bovhyaluronidaze azoximer, increase in SpO2 was recorded: in 7 patients ― after 1 injection (4.2 1.7%), in 24 ― after 2 injections (5.4 0.6%), another 4 patients did not show any significant increase in SpO2 after the first two injections. Increase in SpO2 after the 1st injection inversely correlated with age (r = -0.34; p 0.05) and the initial saturation (r = -0.38; p 0.05). Increase in SpO2 after the second injection correlated with the day of illness on which treatment with bovhyaluronidaze azoximer began (r = -0.36; p 0.05). CONCLUSION: Use of bovhyaluronidaze azoximer in complex treatment for COVID-19 with the lung damage at the inpatient stage can be effective in younger patients with more expressed initial reduction of SpO2, and also in case of administration of the drug in the early stages of the disease. The data obtained in the pilot study, dictate the necessity of studying the level of hyaluronic acid in blood of patients with COVID-19 and lung damage and its role in risk stratification of such patients.
- Open Access
- 7 April 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 4,p. 163-168
Cardiac arrhythmias in patients with bronchial asthma
Introduction. According to modern data, bronchial asthma (BA) is an independent risk factor for the development of cardiac arrhythmias (CA), and the use of long-acting β2-agonists (LABA) in basic therapy may further increase the risks of CA.Aim. To study the structure and risk factors of cardiac arrhythmias in patients with bronchial asthma. Materials and methods. A retrospective study included 181 patients aged 69.4 ± 0.8 years, hospitalized for asthma, with the presence a CA in medical documentation.Results. Among BA patients with CA, supraventricular CA were found in 71.3% (129) patients, ventricular CA in 16.6% (30), combined CA in 12.2% (22). In 52.5% (95) patients, supraventricular extrasystole was detected, in 35.9% (65) – atrial fibrillation, in 28.7% (52) – ventricular extrasystole, in 1.1% (2) – paroxysmal supraventricular tachycardia, in 0.6% (1) – paroxysmal ventricular tachycardia. It was found that supraventricular CA was significantly more frequent among women (χ2 = 5.974, p = 0.05). The severity of BA and the level of control are not related to the type of observed CA (χ2 = 0.755, p = 0.685 and χ2 = 3.003, p = 0.557, respectively).Discussion. The use of a combination of ICS and LABA in basic BA therapy versus the use of ICS alone does not have a significant effect on the frequency and structure of cardiac arrhythmias (χ2 = 1.172, p = 0.556).Conclusion. In hospitalized BA patients, supraventricular cardiac arrhythmias are most often detected, among which supraventricular extrasystole and atrial fibrillation take the main place.
- 7 April 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 4,p. 163-168
Open AccessCardiac arrhythmias in patients with bronchial asthma
Introduction. According to modern data, bronchial asthma (BA) is an independent risk factor for the development of cardiac arrhythmias (CA), and the use of long-acting β2-agonists (LABA) in basic therapy may further increase the risks of CA.Aim. To study the structure and risk factors of cardiac arrhythmias in patients with bronchial asthma. Materials and methods. A retrospective study included 181 patients aged 69.4 ± 0.8 years, hospitalized for asthma, with the presence a CA in medical documentation.Results. Among BA patients with CA, supraventricular CA were found in 71.3% (129) patients, ventricular CA in 16.6% (30), combined CA in 12.2% (22). In 52.5% (95) patients, supraventricular extrasystole was detected, in 35.9% (65) – atrial fibrillation, in 28.7% (52) – ventricular extrasystole, in 1.1% (2) – paroxysmal supraventricular tachycardia, in 0.6% (1) – paroxysmal ventricular tachycardia. It was found that supraventricular CA was significantly more frequent among women (χ2 = 5.974, p = 0.05). The severity of BA and the level of control are not related to the type of observed CA (χ2 = 0.755, p = 0.685 and χ2 = 3.003, p = 0.557, respectively).Discussion. The use of a combination of ICS and LABA in basic BA therapy versus the use of ICS alone does not have a significant effect on the frequency and structure of cardiac arrhythmias (χ2 = 1.172, p = 0.556).Conclusion. In hospitalized BA patients, supraventricular cardiac arrhythmias are most often detected, among which supraventricular extrasystole and atrial fibrillation take the main place.
- Open Access
- 2 January 2022
- Published by Siberian State Medical University in Bulletin of Siberian Medicine
- Vol. 20 (4) , 79-85-85
Effectiveness of antimicrobial therapy for community-acquired pneumonia in real clinical practice
Background. Community-acquired pneumonia (CAP) remains one of the most common infectious diseases, occupying an important place in the structure of mortality worldwide.Aim. To evaluate the effectiveness of antimicrobial therapy for community-acquired pneumonia in hospitalized patients in real clinical practice.Materials and methods. A retrospective, observational study was conducted, which included 236 patients hospitalized for community-acquired pneumonia at the Regional Clinical Hospital in Ryazan in 2019. Based on these case histories, an analysis of the effectiveness of the initial empiric antimicrobial therapy was performed.Results. The initial empiric antimicrobial therapy in 73% of cases included administration of ceftriaxone, in 45% of cases – levofloxacin, in 14% of cases – azithromycin. It was found that initial antimicrobial therapy was effective in 58% of patients who did not require replacement for the antibiotic. A need for a change in the treatment regimen was significantly associated with an increase in the length of hospitalization (p < 0.001), heart rate upon admission (p = 0.032), myelocyte count in the complete blood count (p < 0.001), and urea and blood creatinine levels (p = 0.004 and p = 0.044, respectively). The selected antimicrobial therapy regimen was significantly associated with the expected treatment effectiveness (p = 0.039). The choice of levofloxacin in monotherapy or in combination with ceftriaxone was accompanied by a decrease in the relative risk of replacing the antimicrobial, compared with other treatment regimens (odds ratio (OR) = 0.86 (95% confidence interval (CI): 0.55–1.34) and OR = 0.57 (95% CI: 0.37–0.87), respectively).Conclusion. Empiric antimicrobial therapy for community-acquired pneumonia in real clinical practice complies with current recommendations, however, at the same time, its ineffectiveness persists. Respiratory fluoroquinolones are most effective in treating pneumonia in hospitalized patients.
- 2 January 2022
- Published by Siberian State Medical University in Bulletin of Siberian Medicine
- Vol. 20 (4) , 79-85-85
Open AccessEffectiveness of antimicrobial therapy for community-acquired pneumonia in real clinical practice
Background. Community-acquired pneumonia (CAP) remains one of the most common infectious diseases, occupying an important place in the structure of mortality worldwide.Aim. To evaluate the effectiveness of antimicrobial therapy for community-acquired pneumonia in hospitalized patients in real clinical practice.Materials and methods. A retrospective, observational study was conducted, which included 236 patients hospitalized for community-acquired pneumonia at the Regional Clinical Hospital in Ryazan in 2019. Based on these case histories, an analysis of the effectiveness of the initial empiric antimicrobial therapy was performed.Results. The initial empiric antimicrobial therapy in 73% of cases included administration of ceftriaxone, in 45% of cases – levofloxacin, in 14% of cases – azithromycin. It was found that initial antimicrobial therapy was effective in 58% of patients who did not require replacement for the antibiotic. A need for a change in the treatment regimen was significantly associated with an increase in the length of hospitalization (p < 0.001), heart rate upon admission (p = 0.032), myelocyte count in the complete blood count (p < 0.001), and urea and blood creatinine levels (p = 0.004 and p = 0.044, respectively). The selected antimicrobial therapy regimen was significantly associated with the expected treatment effectiveness (p = 0.039). The choice of levofloxacin in monotherapy or in combination with ceftriaxone was accompanied by a decrease in the relative risk of replacing the antimicrobial, compared with other treatment regimens (odds ratio (OR) = 0.86 (95% confidence interval (CI): 0.55–1.34) and OR = 0.57 (95% CI: 0.37–0.87), respectively).Conclusion. Empiric antimicrobial therapy for community-acquired pneumonia in real clinical practice complies with current recommendations, however, at the same time, its ineffectiveness persists. Respiratory fluoroquinolones are most effective in treating pneumonia in hospitalized patients.